A fight broke out over who has important pieces of RNA interference (RNAi) technology, a strategy to silence genes that could be very lucrative businesses understand how to apply it to human disease. Last week, the Max Planck Society for the Advancement of Science, which supports research at the Max Planck Institutes in Germany, and Alnylam Pharmaceuticals, an RNAi company in Cambridge, Massachusetts, sued three institutions claiming that they had " usurped "inventions" rightfully belong to Max Planck, "according to the suit. the institutions are being pursued Massachusetts Institute of Technology, the Whitehead Institute, and the University of Massachusetts.
the complaint, filed in Suffolk superior Court in Massachusetts, is unusual because many scientists whose work formed the basis of the combination have allegiances on both sides. two co-founders of Alnylam, Nobel Phil price Sharp and David Bartel, are MIT professors.
Several parties involved in the trial, including Alnylam and Max Planck, declined to comment. But essentially, the prosecution argues that some findings on which the three US institutions have rights to patents that cover ways to silence genes with RNAi, rightly belong to Max Planck. Alnylam has an exclusive license for the patent Max Planck; but not to Whitehead, MIT, and the University of Massachusetts patent; according to the lawsuit. Since, Alnylam "risks losing any competitive advantage in the market that would have otherwise," the suit bed Max Planck and Alnylam are lobbying to prevent US agencies to take any other action around their patent RNAi.
0 Komentar